Share Price and Basic Stock Data

Last Updated: November 14, 2024, 3:38 pm

Market Cap	68.5 Cr.
Current Price	66.6
High / Low	66.6/25.0
Stock P/E
Book Value	10.8
Dividend Yield	0.00 %
ROCE	15.9 %
ROE	41.0 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aspira Pathlab & Diagnostics Ltd

Competitors of Aspira Pathlab & Diagnostics Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Global Longlife Hospital and Research Ltd	38.4 Cr.	36.6	61.7/27.0		25.9	0.00 %	2.51 %	4.72 %	10.0
Gian Lifecare Ltd	21.6 Cr.	20.8	29.0/17.0	5.21	19.0	0.00 %	29.2 %	24.6 %	10.0
Fortis Malar Hospitals Ltd	101 Cr.	54.0	108/44.0		15.9	78.7 %	3.29 %	9.12 %	10.0
Family Care Hospitals Ltd	40.5 Cr.	7.50	10.4/6.23	0.98	2.67	0.00 %	15.4 %	24.1 %	10.0
Dr Lalchandani Labs Ltd	7.80 Cr.	18.0	28.9/0.00	9.07	22.4	0.00 %	2.68 %	8.23 %	10.0
Industry Average	27,088.85 Cr	815.13		51.19	89.64	3.80%	11.58%	12.32%	9.00

All Competitor Stocks of Aspira Pathlab & Diagnostics Ltd

Quarterly Result

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Sales	5.88	3.49	4.73	5.44	2.97	3.71	4.37	3.41	2.60	3.32	3.46	3.82	4.64
Expenses	3.45	2.91	3.44	3.38	2.79	3.25	3.56	3.26	2.92	3.68	3.83	3.95	4.29
Operating Profit	2.43	0.58	1.29	2.06	0.18	0.46	0.81	0.15	-0.32	-0.36	-0.37	-0.13	0.35
OPM %	41.33%	16.62%	27.27%	37.87%	6.06%	12.40%	18.54%	4.40%	-12.31%	-10.84%	-10.69%	-3.40%	7.54%
Other Income	0.02	0.02	0.02	0.04	0.06	0.07	0.12	0.07	0.10	0.14	0.10	0.08	0.09
Interest	0.07	0.07	0.08	0.15	0.11	0.11	0.10	0.10	0.10	0.10	0.09	0.08	0.08
Depreciation	0.38	0.38	0.37	0.51	0.42	0.40	0.39	0.38	0.39	0.39	0.38	0.38	0.38
Profit before tax	2.00	0.15	0.86	1.44	-0.29	0.02	0.44	-0.26	-0.71	-0.71	-0.74	-0.51	-0.02
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	2.00	0.14	0.87	1.44	-0.29	0.02	0.44	-0.26	-0.72	-0.71	-0.74	-0.50	-0.02
EPS in Rs	1.94	0.14	0.85	1.40	-0.28	0.02	0.43	-0.25	-0.70	-0.69	-0.72	-0.49	-0.02

Last Updated: October 7, 2024, 8:35 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:58 pm

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	0.00	0.00	0.00	0.00	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	15.24
Expenses	0.02	0.02	0.14	0.23	3.34	8.24	10.88	10.25	11.69	13.16	12.86	14.38	15.75
Operating Profit	-0.02	-0.02	-0.14	-0.23	-2.58	-3.88	-3.24	-1.83	3.52	6.38	1.60	-1.18	-0.51
OPM %					-339.47%	-88.99%	-42.41%	-21.73%	23.14%	32.65%	11.07%	-8.94%	-3.35%
Other Income	0.15	0.02	0.21	0.32	0.31	0.22	0.25	0.29	0.20	0.09	0.32	0.42	0.41
Interest	0.05	0.00	0.00	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35
Depreciation	0.00	0.00	0.00	0.00	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.53
Profit before tax	0.08	0.00	0.07	0.04	-2.73	-5.58	-5.18	-4.21	1.39	4.46	-0.09	-2.67	-1.98
Tax %	37.50%		57.14%	25.00%	0.00%	0.00%	0.00%	0.71%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.05	0.00	0.02	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	-1.97
EPS in Rs	1.25	0.00	0.09	0.13	-5.24	-10.75	-6.32	-4.56	1.34	4.33	-0.09	-2.59	-1.92
Dividend Payout %	0.00%		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2011-2012	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-100.00%	50.00%	-9166.67%	-105.15%	7.17%	18.15%	132.55%	223.19%	-102.02%	-2866.67%
Change in YoY Net Profit Growth (%)	0.00%	150.00%	-9216.67%	9061.52%	112.32%	10.98%	114.40%	90.64%	-325.21%	-2764.65%

Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2011-2012 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	12%
3 Years:	-5%
TTM:	32%

Compounded Profit Growth
10 Years:	%
5 Years:	8%
3 Years:	%
TTM:	78%

Stock Price CAGR
10 Years:	%
5 Years:	13%
3 Years:	-13%
1 Year:	81%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	9%
Last Year:	-41%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:48 pm

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.40	0.40	2.25	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29
Reserves	0.19	0.19	1.36	1.39	0.72	-4.86	-7.93	-10.42	-6.91	-2.43	-2.47	-5.08	0.82
Borrowings	0.06	0.00	0.00	2.62	7.29	11.36	12.52	13.80	7.01	8.85	8.24	7.71	2.48
Other Liabilities	0.01	0.03	0.21	0.03	1.66	0.84	2.02	1.67	1.39	1.42	1.28	1.79	2.17
Total Liabilities	0.66	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	15.76
Fixed Assets	0.00	0.00	0.00	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.16
CWIP	0.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13
Other Assets	0.66	0.62	3.82	6.25	6.82	4.62	5.90	5.64	4.03	8.56	9.33	7.92	9.47
Total Assets	0.66	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	15.76

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2011	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0.04	-0.02	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05
Cash from Investing Activity +	1.35	0.08	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14
Cash from Financing Activity +	-1.33	-0.06	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95
Net Cash Flow	-0.02	0.00	2.25	-2.52	0.94	-2.00	-0.35	3.41	0.17	-0.79	0.24

Free Cash Flow

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-0.08	-0.02	-0.14	-2.85	-9.87	-15.24	-15.76	-15.63	-3.49	-2.47	-6.64	-8.89

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2011	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days				43.22	29.30	38.22	26.01	40.80	83.87	59.07	61.94
Inventory Days				312.86	103.88	45.22	51.36	51.35	46.50	58.40	62.69
Days Payable				730.00	64.58	46.84	73.37	91.60	70.91	51.10	101.70
Cash Conversion Cycle				-373.92	68.61	36.60	4.00	0.55	59.46	66.37	22.93
Working Capital Days				-465.86	1.67	-2.39	-5.20	36.24	81.44	65.63	44.52
ROCE %	10.36%	0.00%	1.82%	-25.39%	-38.41%	-34.49%	-25.15%	19.77%	35.65%	2.01%	-15.87%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	36.25%	36.25%	36.19%	34.55%	19.48%	19.47%	19.37%	18.90%	18.90%	18.72%	18.72%	18.55%
Public	63.75%	63.75%	63.81%	65.45%	80.53%	80.53%	80.64%	81.10%	81.10%	81.29%	81.28%	81.46%
No. of Shareholders	852	868	955	1,141	1,300	1,300	1,371	1,406	1,351	1,512	1,695	1,706

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-2.60	-0.09	4.33	1.45	-4.56
Diluted EPS (Rs.)	-2.60	-0.09	4.33	1.45	-4.95
Cash EPS (Rs.)	-1.10	1.45	5.92	2.75	-2.78
Book Value[Excl.RevalReserv]/Share (Rs.)	9.85	7.60	7.63	3.29	4.09
Book Value[Incl.RevalReserv]/Share (Rs.)	9.85	7.60	7.63	3.29	4.09
Revenue From Operations / Share (Rs.)	12.83	14.05	18.98	14.77	9.06
PBDIT / Share (Rs.)	-0.74	1.86	6.28	3.61	-1.66
PBIT / Share (Rs.)	-2.24	0.31	4.69	2.21	-3.44
PBT / Share (Rs.)	-2.60	-0.08	4.33	1.34	-4.53
Net Profit / Share (Rs.)	-2.60	-0.08	4.33	1.34	-4.56
PBDIT Margin (%)	-5.79	13.24	33.09	24.44	-18.29
PBIT Margin (%)	-17.45	2.27	24.72	14.94	-38.02
PBT Margin (%)	-20.23	-0.61	22.81	9.08	-50.04
Net Profit Margin (%)	-20.23	-0.61	22.81	9.08	-50.38
Return on Networth / Equity (%)	-26.34	-1.13	56.73	40.80	-111.56
Return on Capital Employeed (%)	-18.23	2.08	29.56	23.27	-34.73
Return On Assets (%)	-18.16	-0.51	24.58	11.72	-29.58
Long Term Debt / Equity (X)	0.10	0.12	0.10	0.22	1.20
Total Debt / Equity (X)	0.10	0.12	0.10	0.36	1.81
Asset Turnover Ratio (%)	0.82	0.81	1.31	1.16	0.57
Current Ratio (X)	2.10	3.70	3.99	1.93	0.64
Quick Ratio (X)	1.89	3.44	3.77	1.75	0.58
Inventory Turnover Ratio (X)	6.20	6.22	8.14	8.19	7.14
Interest Coverage Ratio (X)	-2.08	4.59	17.35	4.17	-1.52
Interest Coverage Ratio (Post Tax) (X)	-6.27	0.78	12.97	2.55	-3.19
Enterprise Value (Cr.)	31.60	27.28	65.91	29.40	41.37
EV / Net Operating Revenue (X)	2.39	1.89	3.37	1.93	4.91
EV / EBITDA (X)	-41.27	14.25	10.19	7.91	-26.87
MarketCap / Net Operating Revenue (X)	2.42	1.98	3.41	1.93	4.23
Price / BV (X)	3.15	3.67	8.49	8.67	9.36
Price / Net Operating Revenue (X)	2.42	1.98	3.41	1.93	4.23
EarningsYield	-0.08	0.00	0.06	0.04	-0.11

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Aspira Pathlab & Diagnostics Ltd as of November 15, 2024 is: 67.75

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 15, 2024, Aspira Pathlab & Diagnostics Ltd is Undervalued by 1.73% compared to the current share price 66.60

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Aspira Pathlab & Diagnostics Ltd as of November 15, 2024 is: 50.70

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 15, 2024, Aspira Pathlab & Diagnostics Ltd is Overvalued by 23.87% compared to the current share price 66.60

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -25.16%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of -20.33, which is a positive sign. The stock has a low average Cash Conversion Cycle of -9.62, which is a positive sign.	The stock has a low average ROCE of -5.81%, which may not be favorable. The company has higher borrowings (6.30) compared to reserves (-2.73), which may suggest financial risk. The company has not shown consistent growth in sales (7.60) and profit (-1.26).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
1. Net Profit Margin: -20.23%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -18.23% (Industry Average ROCE: 11.58%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -26.34% (Industry Average ROE: 11.76%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -6.27
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.89
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 39.55)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.1
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Aspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L85100MH1973PLC289209 and registration number is 289209. Currently Company is involved in the business activities of Other human health activities. Company’s Total Operating Revenue is Rs. 19.54 Cr. and Equity Capital is Rs. 10.29 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	Flat No.2, R.D. Shah Building, Shraddhanand Road, Mumbai Maharashtra 400086	info@aspiradiagnostics.com http://www.aspiradiagnostics.com

Management
Name	Position Held
Dr. Haseeb Drabu	Chairman & Ind.Director
Dr. Pankaj J Shah	Managing Director & CEO
Mr. Arvind Karsandas Bhanushali	Executive Director
Mr. Nikunj Mange	Executive Director
Dr. Subhash Raghunath Salunke	Independent Director
Mrs. Mangala K Prabhu	Independent Director
Mr. Avinash C Mahajan	Independent Director
Mr. Manas Mengar	Independent Director

FAQ

What is the latest intrinsic value of Aspira Pathlab & Diagnostics Ltd?

The latest intrinsic value of Aspira Pathlab & Diagnostics Ltd as on 15 November 2024 is ₹67.75, which is 1.73% higher than the current market price of ₹66.60.

What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?

The Market Cap of Aspira Pathlab & Diagnostics Ltd is 68.5 Cr..

What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 15 November 2024?

The current stock price of Aspira Pathlab & Diagnostics Ltd as on 15 November 2024 is ₹66.6.

What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2024?

In FY 2024, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is 66.6/25.0.

What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?

The Stock P/E of Aspira Pathlab & Diagnostics Ltd is .

What is the Book Value of Aspira Pathlab & Diagnostics Ltd?

The Book Value of Aspira Pathlab & Diagnostics Ltd is 10.8.

What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?

The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.

What is the ROCE of Aspira Pathlab & Diagnostics Ltd?

The ROCE of Aspira Pathlab & Diagnostics Ltd is 15.9 %.

What is the ROE of Aspira Pathlab & Diagnostics Ltd?

The ROE of Aspira Pathlab & Diagnostics Ltd is 41.0 %.

What is the Face Value of Aspira Pathlab & Diagnostics Ltd?

The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.